Molecular signatures of tumor progression in pancreatic adenocarcinoma identified by energy metabolism characteristics

Cong Tan1,2,3†, Xin Wang1,2,3†, Xu Wang1,2,3†, Wewei Weng1,2,3, Shu-juan Ni1,2,3, Meng Zhang1,2,3, Hesheng Jiang2,3, Lei Wang1,2,3, Dan Huang1,2,3, Weiqi Sheng1,2,3* and Mi-die Xu1,2,3*

Abstract

Background: In this study, we performed a molecular evaluation of primary pancreatic adenocarcinoma (PAAD) based on the comprehensive analysis of energy metabolism-related gene (EMRG) expression profiles.

Methods: Molecular subtypes were identified by nonnegative matrix clustering of 565 EMRGs. An overall survival (OS) predictive gene signature was developed and internally and externally validated based on three online PAAD datasets. Hub genes were identified in molecular subtypes by weighted gene correlation network analysis (WGCNA) coexpression algorithm analysis and considered as prognostic genes. LASSO cox regression was conducted to establish a robust prognostic gene model, a four-gene signature, which performed better in survival prediction than four previously reported models. In addition, a novel nomogram constructed by combining clinical features and the 4-gene signature showed high-confidence clinical utility. According to gene set enrichment analysis (GSEA), gene sets related to the high-risk group participate in the neuroactive ligand receptor interaction pathway.

Conclusions: In summary, EMRG-based molecular subtypes and prognostic gene models may provide a novel research direction for patient stratification and trials of targeted therapies.

Keywords: Pancreatic adenocarcinoma, Molecular subtype, Energy metabolism-related genes, Prognosis signature

Introduction

Pancreatic adenocarcinoma (PAAD) is one of the most lethal malignancies, causing 459,000 deaths and 432,000 deaths worldwide, according to GLOBOCAN 2018 [1]. Our current understanding of the complicated genetic and epigenetic alterations and their correlation with the microenvironment has not resulted in a leap in patient survival [2]. Substantial effort is required for further exploration of disease pathogenesis and progression and the identification of early detection and risk evaluation biomarkers that will translate to diverse treatment options.

The reprogramming of cellular metabolism plays an indispensable role in tumorigenesis as both a direct and indirect outcome of oncogenic alteration. Reprogramming enables tumor cells to produce ATP to maintain the reduction-oxidation balance and macromolecular biosynthesis processes required for cell growth, proliferation, and migration. For a long time, it was believed that malignancies mainly restrict their energy metabolism to glycolysis, even in the presence of oxygen, a situation known as the Warburg effect [3]. However, an increasing number of studies have acknowledged the heterogeneous metabolic phenotype of cancer cells [4]. For example,
Daemen et al. successfully proposed three highly distinct metabolic subtypes in PAAD through broad metabolite profiling [5]. Although recent bioinformatic analyses have revealed the existence of metabolic subtypes with differential prognosis within PAAD [6], which suggests a relationship between the metabolic genetic expression profile and tumor aggressiveness, almost nothing is known about the potential to define molecular subtypes in PAAD specifically based on the gene expression profiles of energy metabolism-related genes (EMRGs) or how signatures might relate to prognosis. A deep understanding of EMRGs in tumors might provide an important basis for the development of new therapies.

In this study, we constructed energy metabolism-associated molecular subtypes of PAAD by using EMRG expression data from public databases, including TCGA, GEO, and ICGC. Furthermore, we assessed relationships with prognosis and identified differences in clinical and immune characteristics. The prognostic risk model constructed by differentially expressed genes between PAAD molecular subtypes can better evaluate PAAD prognosis. We further used the gene expression datasets from the GEO and ICGC databases to verify the performance of the prognostic risk model.

Materials and methods
Data collection and processing
Raw gene expression data and corresponding clinical information of patients with PAAD were obtained from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and the International Cancer Genome Consortium (ICGC). The RNA-seq expression data, RNA-seq count data, and clinical follow-up information of 177 patients diagnosed with PAAD were downloaded through the TCGA GDC API; among them, 171 patients (90%) were randomly selected as the training set for model construction (Table 1). Subsequently, to verify the robustness of the model over different sequencing platforms, all PAAD samples in TCGA database were used as internal verification sets. Furthermore, a GEO dataset, GSE57495, containing transcriptome and clinical data of 63 patients and a series of RNA-seq profiles of 269 samples obtained from the ICGC database, was downloaded for validation datasets (Table 1). Eleven annotated metabolism-related pathways from the Molecular Signature Database v7.0 (MSigDB), which included 594 EMRGs, were downloaded from the Reactome database [7].

Identification of energy metabolism molecular subtypes
Among all TCGA and ICGC PAAD samples, 565 EMRGs were extracted. Nonnegative matrix factorization (NMF) [7] was utilized to cluster all PAAD samples, and the optimal numbers of clusters were determined according to indicators including cophentic correlation [7], silhouette coefficient [8], and residual sum of squares (RSS) [9].

Analysis of immune scores between molecular subtypes
The fragments per kilobase of exon model per million mapped reads (FPKM) data of genes in the TCGA PAAD dataset were submitted to the TIMER (tumor immune estimation resource) tool [10] and the R software package estimate for calculation of the immune score. Next, the difference in the immune score and stromal score, which represent the relative proportion of immune cells and stromal cells in tumor tissues, was calculated using the R package estimation of stromal and immune cells in malignant tumors using expression data (ESTIMATE) [11]. The estimate score, which refers to the purity of tumor tissues, is the sum of the immune score and...
stromal score. Then, the differences in the immune scores of the samples between the two subtypes were compared.

**Identify differentially coexpressed genes between molecular subtypes**

To identify the differentially coexpressed genes between each subtype, the R software package DESeq2 was used to calculate the differentially expressed genes (DEGs) between the two subtypes, and the thresholds were set to FDR < 0.05 and | log2FC | > 1. The weighted gene correlation network analysis (WGCNA) coexpression algorithm was used to detect coexpressed genes and modules by the R package WGCNA [12]. To improve the accuracy of network construction, the TPM profiles of genes were subjected to hierarchical cluster analysis to remove outlier samples. Second, the distance between each gene was calculated using the Pearson correlation coefficient; a weighted coexpression network was constructed using the R package WGCNA, and coexpression modules were screened by setting the soft threshold power β to 10. Third, the topology overlap matrix (TOM) was then constructed from the adjacency matrix to avoid the influence of noise and spurious associations. On the basis of TOM, average-linkage hierarchical clustering using the dynamic shear tree method was subsequently conducted to define coexpression modules, and the minimum gene size of each module was set as 30. The feature vector values (eigengenes) of each module were calculated in turn to explore the relationship among modules, and then modules with highly correlated eigengenes were merged into new modules by performing cluster analysis with the following thresholds: height = 0.25, DeepSplit = 2, and minModuleSize = 30. To identify the modules of interest, the correlation between each coexpression module and patients’ clinical features as well as cluster subtypes was further evaluated. Modules with a significant correlation with the energy metabolism subtypes were defined as key modules for the subsequent selection of hub genes (Spearman correlation coefficient > 0.4, P < 0.05). Finally, pathway enrichment analysis of differentially coexpressed genes was performed using the R package WebGestaltR (threshold FDR < 0.05).

**Establishment of prognosis prediction model**

The R package survival coxph function was used for analysis of the univariate Cox proportional hazards regression model, and log rank P < 0.01 was selected as the threshold. To narrow the gene range and maximize the accuracy, least absolute shrinkage and selection operator (LASSO) Cox regression analysis [13], a method for screening signatures with generally effective prognostic performance by performing automatic feature selection, was performed by using the glmnet package of R to identify the prognostic genes. Optimal genes were evaluated by 10-fold cross validation. Genes obtained by LASSO analysis were subjected to multivariate Cox survival analysis to construct a final prognostic risk model. Time-dependent receiver operating characteristic (ROC) curve analysis was conducted to assess the prognostic value of the identified model using the R package timeROC [14]. The risk scores of patients in the internal verification set and the external verification set were analyzed using the same model coefficients as the training set to verify the robustness of the gene signature. Kaplan–Meier curves were used to evaluate the difference in survival time between groups, and then univariate and multivariate Cox regression analyses were performed to evaluate independent prognostic factors. A P value < 0.05 was considered statistically significant. Decision curve analysis (DCA), which can evaluate predictive models from the perspective of clinical consequences [15], was performed in the entire cohort to test the clinical usefulness of the nomogram in comparison with the gene signature and clinicopathological parameters. A restricted mean survival time (RMST) curve was drawn to construct the comparison with the R package rms.

**Bioinformatic analysis**

Data processing and symbol remapping were conducted using R-4.0.1 software. A P value < 0.05 was considered statistically significant. Single-sample gene set enrichment analysis (ssGSEA) was applied to identify the relationship between the risk scores of different samples and biological functions using the R package GSVA. The classical gene sets of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (c2.cp.kegg.v7.0.symbols) were considered to decipher the phenotype [16–18]. For each analytical pathway, the enrichment score (ES) and the significance of ES were calculated, and the normalized enrichment score (NES) and false discovery rate (FDR) were further calculated to examine functional enrichment results.

(See figure on next page.)

**Fig. 1** Identification of molecular subtypes in PAAD. A Consensus map of NMF clustering in TCGA PAAD dataset; B Kaplan–Meier curves showing the overall survival (OS) curve of the two subtypes in TCGA PAAD dataset; C Consensus map of NMF clustering in ICGC PAAD dataset; D Kaplan–Meier curves showing the overall survival (OS) curve of the two subtypes in ICGC PAAD dataset; E The proportions of B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells (DCs) between the two subtypes; F Distribution of the ImmuneScore, StromalScore, and ESTIMATEScore between the two subtypes.
Fig. 1 (See legend on previous page.)
**Result**

**Construction of energy metabolism-related molecular subtypes**

By using NMF analysis based on the expression of the 565 EMRGs (Supplementary Fig. 2A), we identified two distinct subtypes (Cluster 1 \( n = 74 \), Cluster 2 \( n = 97 \)) between the 171 patients in the TCGA PAAD dataset (Fig. 1A-B). Clinically, patients in Cluster 1 showed a significantly higher tumor grade than those in Cluster 2 (Supplementary Fig. 2C). Moreover, we assessed the potential difference in prognosis between the two subtypes, and patients in Cluster 1 had significantly better OS compared with patients in Cluster 2 \( (p = 0.017, \text{HR} = 0.597, 95\% \text{CI} 0.383–0.914, \text{Fig. 1B}). \) Similarly, the expression profiles of these 565 EMRGs also divided 257 patients into two molecular subtypes in the ICGC PAAD dataset (Fig. 1C-D, Supplementary Fig. 2B), and patients in Cluster 1 also showed significantly better OS compared with patients in Cluster 2 \( (p = 0.003, \text{HR} = 0.610, 95\% \text{CI} 0.441–0.844, \text{Fig. 1D}). \) These data show the consistency of these molecular subtypes in PAAD.

Then, we calculated the immune scores of six cell types (B cells, CD4 T cells, CD8 T cells, neutrophils, macrophages, and dendritic cells) in each PAAD sample and analyzed the potential difference between Cluster 1 and Cluster 2. The results showed that except for the B cell immune score, Cluster 1 showed a higher immune score than Cluster 2 (Fig. 1E). We further observed that the scores of immunity, stroma, and tumor purity in Cluster 1 were also significantly higher than those in Cluster 2 (Fig. 1F). These results indicate that lower immune cell infiltration in the tumor environment (TME) may confer worse prognosis in patients with PAAD.

**Identification of differentially coexpressed genes between subtypes**

We extracted the expression profile of protein-coding genes from the TCGA PAAD dataset and clustered all samples through hierarchical clustering (Supplementary Fig. 3A), from which we confirmed that there was no outlier sample. To ensure that the network constructed by WGCNA was scale-free, \( \beta \) was set as 10 (Supplementary Fig. 3B). Then, we performed cluster analysis and obtained 14 modules, among which the gray module represented gene sets that could not be aggregated to other modules (Fig. 2A). Moreover, by analyzing the correlation of the module and genes in the module with phenotypes (Supplementary Table 2), we found that the blue module (containing 1692 coexpressed genes) was significantly correlated with Cluster 1, and the yellow module (containing 645 coexpressed genes) was significantly correlated with Cluster 2 (Fig. 2B-D). In addition, we identified 2411 DEGs differentially expressed genes (DEGs) between Cluster 1 and Cluster 2, comprising 1641 upregulated DEGs and 770 downregulated DEGs (Fig. 2E-F, Supplementary Table 3). We further analyzed these 2411 DEGs and their coexpressed genes in the blue and yellow modules and identified 743 overlapping genes (Supplementary Table 4). These 743 coexpressed DEGs were analyzed by GO function and KEGG pathway enrichment (Supplementary Table 5), and 38 KEGG pathways, 52 GO cellular component (CC), 126 GO molecular function (MF), and 977 GO biological process (BP) were enriched. The top enriched pathways included cell adhesion molecules (CAMs), transcriptional misregulation in cancer, immunological synapses, and T cell differentiation (Supplementary Fig. 3C-F), suggesting that these coexpressed DEGs may be involved in the PAAD molecular regulatory network by performing pivotal functions through these pathways.

**Development of a prognostic risk model based on coexpressed DEGs**

By analyzing the expression profiles of 743 coexpressed DEGs and the corresponding survival of the training set using a univariate Cox proportional hazard regression model, we identified sixty-seven prognostic coexpression DEGs \( (p < 0.01, \text{Supplementary Table 6}). \) After Lasso Cox regression analysis and 10-fold cross validation, we selected four genes \( (\lambda = 0.1042) \) as candidate genes for construction of the prognostic risk model (Supplementary Fig. 4A-B). We then established a gene-based prognostic model by using univariate Cox regression analysis (Table 2). High expression levels of GJB5, MET, and TMEM139 were identified as risk factors, whereas AFF3 was identified as a protective factor. The final 4-gene signature formula is as follows: RiskScore = \(-0.1513 \times \text{expAFF3} + 0.0156 \times \text{expGJB5} + 0.0045 \times \text{expMET} + 0.0164 \times \text{expTMEM139}\). We calculated the risk score of each sample according to the established model and plotted the risk score distribution, which showed that the survival time of the samples with high risk scores was significantly shorter than that of those with low risk scores (Fig. 3A). In addition, the AUCs of the 1-, 3-, and 5-year ROC curves for the 4-gene signature to predict PAAD survival were all above 0.70 (Fig. 3B). Finally, we performed Z-score...
Fig. 2 (See legend on previous page.)
normalization on the risk score, which classified samples with a risk score greater than zero into the high-risk group and samples with a risk score less than zero into the low-risk group. Kaplan-Meier survival analysis demonstrated that there were significant differences between the high- and low-risk groups (log rank $P < 0.001$, HR = 2.413, Fig. 3C). We further obtained the subtype schema of samples in the TCGA PAAD cohort [19] and compared the difference in risk scores between basal and classic samples. We observed that basal samples had a significantly higher risk score than classical samples (Supplementary Fig. 4C).

Table 2 Univariate Cox regression of the 4-gene signature

| Symbol | coefficient | Hazard ratio | Z-score | $P$ value | Low 95%CI | High 95%CI |
|--------|-------------|--------------|---------|-----------|-----------|------------|
| AFF3   | -0.1513     | 0.8595       | -1.7450 | 0.0809    | 0.7252    | 1.0190     |
| GJB5   | 0.0156      | 1.0157       | 3.4580  | 0.0005    | 1.0068    | 1.0250     |
| MET    | 0.0045      | 1.0045       | 2.3600  | 0.0183    | 1.0008    | 1.0080     |
| TMEM139| 0.0164      | 1.0165       | 1.8980  | 0.0577    | 0.9995    | 1.0340     |

Fig. 3 Construction of the 4-gene signature in the training dataset. A Risk score, survival time, survival status, and expression of the 4-gene signature in the training set; B ROC curve of the 11-gene signature for 1-year, 3-year, and 5-year survival in the training set. C Kaplan-Meier survival analysis of overall survival for high-risk or low-risk group patients in the training set. ROC, receiver operating characteristic; AUC, area under the curve; HR, hazard ratio; CI, confidence interval
Internal and external validation of the prognostic risk model
To determine the robustness of the model, we subjected patient data from the entire TCGA dataset to our prognostic gene signature formula. The risk score distribution of all samples (Fig. 4A), corresponding ROC curves (Fig. 4B), and Kaplan–Meier survival curves (Fig. 4C) showed that the AUCs of the signature remained high, and the high-risk groups had consistently shorter OS than the low-risk groups.

However, we noticed that 27 samples in the TCGA cohort were not exactly pancreatic ductal adenocarcinoma. Among them, ten samples were normal pancreas with atrophy, eight samples were neuroendocrine neoplasms, four samples were tumors derived from other organs (duodenum-ampulla in three cases and undefined location in one case), two samples were intraductal papillary neoplasms, one sample was an acinar cell carcinoma, one was a ductal adenocarcinoma but had received neoadjuvant chemotherapy and one had a normal ampulla [20]. Therefore, we further subjected patients’ data of the 146 exactly PAAD cases from the TCGA cohort to our prognostic gene signature formula (Fig. 4D). The corresponding ROC curves (Fig. 4E) showed high AUCs similar to the whole TCGA cohort. And Kaplan–Meier survival results also showed that patients in the high-risk groups had consistently shorter OS than the low-risk groups (Fig. 4F). Therefore, we believe that the impact of these 27 samples on the remaining 150 samples is acceptable. We further verified the robustness of the 4-gene prognosis signature by external analysis in the GSE57495 dataset (Fig. 5A-C) and ICGC PAAD dataset (Fig. 5D-F) using the same coefficients in our prognostic gene signature formula. Excellent performance was observed in the prognostic risk indication.

Independence of the 4-gene prognostic signature
To assess the independence of the 4-gene signature in clinical application, we conducted univariate and multivariate Cox regression in the TCGA PAAD dataset. We systematically analyzed the clinical data of patients, including age, sex, pathologic T stage, pathologic N stage, pathologic M stage, tumor stage, tumor grade, Basal/classical phenotype [19] and the 4-gene signature. Univariate Cox regression analysis showed that age, tumor grade, pathologic T stage, pathologic N stage, tumor stage, and the 4-gene signature were significantly associated with survival (P < 0.05, Fig. 6A). However, multivariate Cox regression analysis revealed that only the 4-gene signature (Fig. 6B) were independent prognostic indicators in PAAD. The above conditions indicated that the 4-gene signature has good predictive performance in clinical application.

Furthermore, we combined clinical features and the 4-gene signature and constructed a nomogram using the entire TCGA PAAD dataset (Fig. 6C). The nomogram suggested that the 4-gene signature had the greatest impact on the survival rate prediction. We calibrated the performance of 1-, 2-, and 3-year nomography data for visualization of the nomogram, which further verified the consistency between the predicted and actual survival (Fig. 6D).

Comparison with previous prognostic models
Previous studies have identified several prognostic models for PAAD survival. The predictive performance of the present 4-gene signature was further compared with four previous models (a 15-gene signature proposed by Chen et al. [21], a 7-gene signature proposed by Cheng et al. [22], a 5-gene signature proposed by Raman et al. [23], and a 7-gene signature proposed by Magouliotis et al. [24]). We calculated the risk score of each PAAD sample in the TCGA PAAD dataset based on the corresponding coefficients provided by each model, evaluated the ROC of each model, and divided the samples into high-risk and low-risk groups based on the median risk score of each signature. All four models divided the patients into a high-risk group and a low-risk group (Supplementary Fig. 5). Kaplan–Meier curves showed that there were significant differences between the high-risk and low-risk groups in the Chen, Cheng, and Raman models (P < 0.05) but no significant difference for the Li model (P = 0.076, Supplementary Fig. 5A-D). Among the four models, the AUCs of the Chen model and Raman model were greater than 0.70, but generally, the predictive efficacy of the four models was worse than that of our four-gene model (Supplementary Fig. 5E-H). Furthermore, RMST curves (Fig. 7A) and DCA curves (Fig. 7B) were used to evaluate the predictive effect of our 4-gene signature and the four published models on the prognosis of PAAD patients, and both curves demonstrated that the performance of our four-gene model was significantly better than that of the previous four models.

GSEA of enriched pathways based on risk score
To investigate the relationship between the risk score and biological function of different samples, we conducted single sample GSEA (ssGSEA) analysis and calculated
Fig. 4 (See legend on previous page.)
the ssGSEA score of each sample on different biological functions. The correlation between these functions and the RiskScore with a coefficient cutoff of 0.4 showed that most of the functional pathways were negatively correlated with the RiskScore of the samples (Fig. 8A). Moreover, we divided the training set into a high-risk group and a low-risk group according to the risk score. GSEA was used to analyze the significantly enriched pathways in the two groups (Supplementary Table 7). Pathways including bladder cancer, the pentose phosphate pathway, the p53 signaling pathway, and thyroid cancer were significantly negatively correlated with the low-risk group, whereas the neuroactive ligand receptor interaction pathway was negatively correlated with the high-risk group (P < 0.01, Fig. 8B).

Discussion
Cumulative evidence has revealed that metabolic reprogramming in cancer is extensively linked to oncogenesis and immune disorders [25, 26]. In PAAD, previous studies suggested that the metabolic alteration in PAAD was typically characterized by the overexpression of glycolytic enzymes and lactate dehydrogenase for glucose, amino acid, and lipid metabolism [27, 28]. Moreover, there is complex crosstalk among these reprogrammed metabolic pathways within the tumor microenvironment, which contributes to the extraordinary growth advantages of tumor cells and unlimited development of PAAD [28].

The detection of aberrant metabolomics also contributes to the identification of novel biomarkers for diagnosis and prognosis and the discovery of potential therapeutic targets for PAAD. For example, there are significant differences in metabolic profiles not only between PAAD patients and normal controls but also among different pathological PAAD subtypes [29, 30], and metabolic alterations have helped identify several promising metabolomics-based diagnostic biomarkers, such as single serum metabolites [31] and even metabolomics-based biomarker signatures in blood [32]. Oliver F. Bathe et al. proposed the utility of serum metabolomic profiling in discriminating PAAD patients from healthy controls [33]. PAAD patients with higher levels of PE in serum exosomes might have a worse prognosis according to a population-based study [34]. Taken together, the distinct characteristics of energy metabolism in PAAD are worth exploring and may shed new light on the development of novel biomarkers related to metabolism. However, the accurate detection of metabolites in biological samples remains hampered by some technical defects, such as a lack of optimized study methods, limited coverage in metabolomics fingerprints, and interference caused by unwanted sources [35]. Moreover, the abundance of some metabolites can be quite low and fall below the detection limit [36]. Gene expression profiling, with the advantage of being convenient and precise, can provide a complete picture of tumor properties based on quantitative data [37]. By analyzing the expression levels of EMRGs in PAAD tumor tissue, the metabolic characteristics of PAAD can be comprehensively interpreted from another dimension.

In the present study, a total of 565 EMRGs were selected from the Reactome database. These genes mainly participate in the key pathways of carbohydrate, fatty acid, and glycogen metabolism. Based on the expression data of the TCGA-PAAD dataset, pancreatic cancer patients were divided into two metabolic subtypes using the NMF algorithm. Significant differences were observed in patients’ immune cell infiltration and survival status between the two subtypes. Moreover, the proportions of nearly all immune cells and the fraction of immune components were significantly higher in the subtype with significantly better clinical outcomes, which strongly indicates the close relationship between tumor energy metabolism and immunology in PAAD. Previous evidence has shown that metabolic interventions can impact the immune functions of immune cells upon activation [38, 39]. This phenomenon revealed the potential influence of the cross-talk between energy metabolism and the immune microenvironment on the development and long-term survival of PAAD.

To select the hub genes that may significantly modulate cancer metabolism in PAAD, WGCNA coexpression analysis was conducted, and a total of 743 genes that strongly correlated with the two metabolic subtypes and were differentially expressed between the two subtypes were identified and considered as candidates for the construction of a prognostic model. Using Lasso regression analysis, a four-gene (AFF3, GJB5, MET, and TMEM139) signature was identified after the verification of the training, internal validation sets, and external validation sets, which comprised

(See figure on next page.)

**Fig. 5** External validation of the robustness of the 4-gene signature in the GSE57495 and ICGC PAAD cohorts. A Risk score, survival time, survival status, and expression of the 4-gene signature in the GSE57495 dataset; B ROC curve of the 4-gene signature for 1-year, 3-year, and 5-year survival in the GSE57495 cohort; C Kaplan–Meier survival curve based on the 4-gene signature in the GSE57495 cohorts; D Risk score, survival time, survival status, and expression of the 4-gene signature in the ICGC PAAD dataset; E ROC curve of the 4-gene signature for 1-year, 3-year, and 5-year survival in the ICGC PAAD cohort; F Kaplan–Meier survival curve based on the 4-gene signature in the ICGC PAAD cohorts. ROC, receiver operating characteristic; AUC, area under the curve; HR, hazard ratio; CI, confidence interval
Fig. 5 (See legend on previous page.)
a total of 491 patients from the TCGA, ICGC, and GEO PAAD datasets. The model translated the gene expression information into a risk score for the accurate estimation of prognosis in PAAD. Notably, the 3-year AUCs for the signature in all datasets were solid (higher than 0.70). When clinicopathologic parameters were taken into consideration, the constructed risk score system still independently predicted the prognosis of PAAD patients. A nomogram integrating the calculated risk score and clinical information constructed for the accurate prediction of survival

![Figure 6](image-url)

**Fig. 6** Independence of the 4-gene prognosis signature. A-B Forest plot of the univariate (A) and multivariate (B) Cox regression analyses in the TCGA PAAD dataset; C A nomogram was developed by integrating the signature risk score with the clinicopathologic features in the TCGA PAAD dataset. D Calibration curves of the nomogram for predicting OS at 1 year, 3 years and 5 years in the TCGA PAAD dataset
probability of PAAD patients also showed confident clinical utility in PAAD.

Although there were 27 non-PAAD samples in the TCGA cohort, they are exactly pancreatic carcinoma. We also used those 146 PAAD samples for survival analysis, and observed that the high risk-score samples have a significantly worse prognosis, and the formula also showed similarly higher AUC in these PAAD samples. In addition, we had verified the good robustness of the 4-gene signature by two pancreatic ductal adenocarcinoma datasets from ICGC and GEO database. Therefore, we believe that the impact of these 27 samples on the remaining 146 samples is acceptable. This may also be the reason why other recent PAAD relayed prognostic models also did not exclude these 27 samples [22, 23].

Among the four genes, GJB5, MET, and TMEM139 were risk factors, whereas AFF3 was a protective factor for clinical outcomes in PAAD. The prognostic value of MET in PAAD has been reported in previous studies [40, 41]. MET is a well-recognized regulator in the progression of PAAD, and MET inhibitors have shown promising results in preclinical studies [42, 43]. However, the risk or protective value of the other three genes in PAAD have rarely been identified. Functional enrichment analysis revealed that this metabolism-related signature was significantly involved in some classical cancer-related pathways. The interaction between the four genes and tumor metabolism and progression in PAAD deserves further investigation.

Several previous studies have also identified specific prognostic models for the risk prediction of PAAD. For example, Chen et al. proposed a 15-gene signature that contained C6orf15, CAPN8, HIST1H3H, IGF2BP3, KIF14, KRT6A, PMAIP1, PPBP, RTKN2, SCEL, SERPINB5, SLC2A1, SLC45A3, TMPRSS3, and UCA1 [21]. Cheng et al. identified a biomarker consisting of 7 genes, including SCEL, SLC2A1, and SERPINB5, which were in Chen’s gene signature [22]. Raman et al. discovered another 5-gene signature based on the gene expression levels of ADM, ASPM, DCBLD2, E2F7, and KRT6A [23], which are distinct from the genes in the previous two modules. Magouliotis et al. discovered another gene signature containing 3 protein-coding RNAs and 4 microRNAs that was totally different from that of Jiang et al. [24]. The prognostic performance of the present model was further compared with that of the four previous models. Among the four different signatures, our four-gene biomarker had the highest AUC and C-index values. It could be concluded that these EMRGs outperform some previous biomarkers in the survival prediction of PAAD patients and have great potential to be used in clinical applications in the future.

However, there are still some limitations of this study. For example, the analysis was based on retrospective data and needs to be verified in a prospective cohort containing samples from multiple centers before clinical application. Deeper mechanistic research is also needed to elucidate the exact functions of the identified signature in PAAD.
Fig. 8 ssGSEA results according to the risk score of PAAD samples in the TCGA dataset. A Clustering of KEGG pathways correlated with RiskScore, with correlation coefficients greater than 0.40; B Enrichment pathways that were significantly correlated in the high-risk and low-risk groups.
Conclusion
In summary, by analyzing the expression levels of EMRGs in PAAD tumor tissues, two different clusters with varied overall survival and immune status were identified in the TCGA PAAD dataset. A 4-gene prognostic signature and a novel nomogram were identified for the accurate risk prediction of PAAD patients.

Abbreviations
PAAD: Primary pancreatic adenocarcinoma; EMRG: Energy-metabolism-related gene; OS: Overall survival; WGCNA: Weighted gene correlation network analysis; ROC: Receiver operating characteristic; GSEA: Gene set enrichment analysis; TCGA: The Cancer Genome Atlas; GEO: Gene Expression Omnibus; ICGC: International Cancer Genome Consortium; MSigDB: Molecular Signature Database; IRB: Institutional review board; FUSCC: Fudan University Shanghai Cancer Center; NMF: Nonnegative matrix factorization; RSS: Residual sum of squares; FPKM: Fragments per kilobase per million; TOM: Topology overlap matrix; LASSO: Least absolute shrinkage and selection operator; DCA: Decision curve analysis; RMST: Restricted mean survival time; ES: Enrichment score; NES: Normalized enrichment score; FDR: False discovery rate.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-09487-3.

Acknowledgments
The authors would like to thank all researchers who contributed to the TCGA, GEO, and ICGC datasets included.

Authors’ contributions
WS and MX designed the study. Both XW and CT conducted the data processing, model establishment, and visualization of the analysis. MX, CT, MY, both XW and WW performed the data analysis and interpretation. SN and MZ performed statistical analysis. CT, LW, WS, and MX planned and supervised the project and wrote the manuscript. CT and DH revised the manuscript. All authors have read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (81972249, 81602078, 81802367, 81802361), Shanghai Clinical Research Plan of SHDC (SHDC2020CR4068), Shanghai Nova Young Medical Talents Funding Program, Shanghai Health Personnel (2020 No. 087), Shanghai Clinical Science and Technology Innovation Project of Municipal Hospital (SHDC12020102), Fudan University’s 2019 “Double First-class” Original Research Personalized Support Project (XM03190634), Shanghai Science and Technology Development Fund (18ZR140800, 17ZR1406500), Shanghai Science and Technology Development Fund (19MC1911000), Clinical Research Project of Shanghai Municipal Health Committee (2019Y0348), Shanghai “Rising Stars of Medical Talents” Youth Development Program Youth Medical Talents – Specialist Program (SHWSRS(2020)_087), Shanghai Anticancer Association EYAS Project (SACA-CY19B10), and Hospital Foundation of Fudan University Shanghai Cancer Center (YMS201907, YQHN201906, YJ201704).

Availability of data and materials
The datasets generated and analyzed during the current study are available in the TCGA repository (https://portal.gdc.cancer.gov/), ICGC database (https://dcc.icgc.org/repositories), and GEO repository (GSE57495, https://www.ncbi.nlm.nih.gov/geo/query/acc?acc=GSE57495).

Declarations
Patient approval and consent to participate
The patients involved in this study were approved by the institutional review board (IRB) of Fudan University Shanghai Cancer Center (FUSCC) and conducted in accordance with the Helsinki Declaration.

Consent for publication
Not applicable.

Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author details
1Department of Pathology, Fudan University Shanghai Cancer Center, 270 Dong’an Road, Shanghai 200032, People’s Republic of China. 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. 3Institute of Pathology, Fudan University, Shanghai 200032, China.

Received: 30 April 2021 Accepted: 4 April 2022
Published online: 13 April 2022

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
2. Storz P, Crawford HC. Carcinogenesis of pancreatic ductal adenocarcinoma. Gastroenterology. 2020;158(8):2072–81.
3. Liberti MV, Locasale JW. The Warburg effect: how does it benefit Cancer cells? Trends Biochem Sci. 2016;41(3):211–8.
4. Nayak AP, Kapur A, Barroilhet L, Patankar MS. Oxidative phosphorylation: a target for novel therapeutic strategies against ovarian Cancer. Cancers. 2018;10(9).
5. Daemen A, Peterson D, Sahu N, McCord R, Du X, Liu B, et al. Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc Natl Acad Sci U S A. 2015;112(32):E4410–7.
6. Espiau-Romera P, Courtou S, Parejo-Alonso B, Sancho P. Molecular and metabolic subtypes correspondence for pancreatic ductal adenocarcinoma classification. J Clin Med. 2020;9(12).
7. Brunet JP, Tamayo P, Golub TR, Mesirov JP. Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A. 2004;101(12):4164–9.
8. Lovmar L, Ahlford A, Jonsson M, Syvänen AC. Silhouette scores for assessment of SNP genotype clusters. BMC Genomics. 2005;6:35.
9. Som of Squares: Residual Sum, Total Sum, Explained Sum. https://www.statisticshowto.com/residual-sum-squares/
10. Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, et al. Comprehensive analyses of tumor immunity implications for cancer immunotherapy. Genome Biol. 2016;17(1):174.
11. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
12. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC bioinformatics. 2008;9:559.

13. Hughey JJ, Butte AJ. Robust meta-analysis of gene expression using the elastic net. Nucleic Acids Res. 2015;43(12):e79.

14. Blanche P, Dartigues JP, Jacquemin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32(30):5381–97.

15. Kerr KF, Brown MD, Zhu K, Janes H. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(21):2534–40.

16. Kanehisa M, Furumichi M, Sato Y, Ishiguro-Watanabe M, Tanabe M. KEGG: integrating viruses and cellular organisms. Nucleic Acids Res. 2021;49(D1):D545–551.

17. Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein Sci. 2019;28(11):1947–51.

18. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.

19. Rashid NU, Peng XL, Jin C, Moffitt RA, Volmar KE, Belt BA, et al. Purity markers: is it necessary? Metabolomics. 2019;15(6):86.

20. Qin C, Yang G, Yang J, Ren B, Wang H, Chen G, et al. Metabolism of chemotherapeutic agents in cancer: metabolic profiling for the detection of pancreatic cancer: large independent validation study. Pancreas. 2016;45(10):1418–23.

21. Chen DT, Davis-Yadley AH, Huang PY, Husain K, Centeno BA, PermuWey J, et al. Prognostic fifteen-gene signature for early stage pancreatic ductal adenocarcinoma. PLoS One. 2015;10(8):e0133562.

22. Cheng Y, Wang K, Geng L, Sun J, Xu W, Liu D, et al. Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma. EBioMedicine. 2019;40:382–93.

23. Raman P, Maddipati R, Lim KH, Tozeren A. Pancreatic cancer survival analysis defines a signature that predicts outcome. PloS One. 2018;13(8):e0201751.

24. Magoulitis DE, Sakellariou N, Dimas K, Tasiopoulou VS, Svokos KA, Svokos AA, et al. In silico transcriptomic analysis of the chloride intracellular channels (CLIC) Interactome identifies a molecular panel of seven prognostic markers in patients with pancreatic ductal adenocarcinoma. Curr Genomics. 2020;21(2):119–27.

25. Andrejeva G, Rathmell JC. Similarities and distinctions of Cancer and immune metabolism in inflammation and tumors. Cell Metab. 2017;26(1):49–70.

26. Hirshcoy MD, DeBerardinis RJ, Diehl AME, Drew JE, Frezza C, Green MF, et al. Dysregulated metabolism contributes to oncogenesis. Semin Cancer Biol. 2015;35(Suppl):S129–50.

27. Chan AK, Bruce JJ, Srivardena AK. Glucose metabolic phenotype of pancreatic cancer. World J Gastroenterol. WJG. 2016;22(12):3471–85.

28. Qin C, Yang G, Yang J, Ren B, Wang H, Chen G, et al. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer. 2020;19(1):50.

29. Liang C, Qin Y, Zhang B, Ji S, Si S, Xu W, Liu J, Xiang J, Liang D, Hu Q, et al. Energy sources identify metabolic phenotypes in pancreatic cancer. Acta Biochim Biophys Sin. 2016;48.

30. Follia L, Ferrero G, Mandili G, Becucci M, Giordano D, Spadi R, Satolli MA, Evangelista G, Katayama H, Hong W, et al. Integrative Analysis of Novel Metabolic Subtypes in Pancreatic Cancer Fosters New Prognostic Biomarkers. Front Oncol. 2019;9(115).

31. Akita H, Ritchie SA, Takemasa J, Eguchi H, Pastural E, Jin W, et al. Serum metabolite profiling for the detection of pancreatic Cancer: results of a large independent validation study. Pancreas. 2016;45(10):1418–23.

32. Mayerle J, Kalthoff H, Peszka R, Kamlage B, Peter E, Schniewendt B, et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut. 2018;67(1):128–37.

33. Bathe OF, Shaykhutdinov R, Kopiczuk K, Weljie AM, McKay A, Sutherland FR, et al. Feasibility of identifying pancreatic Cancer based on serum metabolomics. Cancer Epidemiol Biomark Prevention. 2011;20(1):140–7.

34. Tiko L, Zhou J, Yuan C, Zhang L, Li D, Di S, et al. Metabolomics identifies serum and exosomes metabolic markers of pancreatic cancer. Metabolomics. 2019;15(6):86.

35. Scalbert A, Brennan L, Fiehn O, Hankemeier T, Kristal BS, van Ommen B, et al. Mass-spectrometry-based metabolomics: limitations and recommendations for future progress with particular focus on nutrition research. Metabolomics. 2009;5(4):435–58.

36. Kang YP, Ward NP, DeNicola GM. Recent advances in cancer metabolism: a technological perspective. Exp Mol Med. 2018;50(4):31.

37. Nevins JR, Potti A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet. 2007;8(8):601–9.

38. O’Sullivan D, Sanin DE, Pearce EI, Pearce EL. Metabolic interventions in the immune response to Cancer. Nat Rev Immunol. 2019;19(5):324–35.

39. Biswas SK. Metabolic reprogramming of immune cells in Cancer progression. Immunity. 2015;43(3):435–49.

40. Lux A, Kahlert C, Grützmann R, Pilarsky C. c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer. Int J Mol Sci. 2019;20(13).

41. Zhu GH, Huang C, Qiu ZJ, Liu J, Zhang ZH, Zhao N, et al. Expression and prognostic significance of CD151, c-met, and integrin alpha3/alpha5 in pancreatic ductal adenocarcinoma. Dig Dis Sci. 2011;56(4):1090–8.

42. Qian LW, Mizumoto K, Inadome N, Nagai E, Sato N, Matsumoto K, et al. Radiation stimulates HGF receptor/c-met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int J Cancer J Int du Cancer. 2003;104(5):542–9.

43. Rucki AA, Xiao Q, Muth S, Chen J, Che X, Kleponis J, et al. Dual inhibition of hedgehog and c-met pathways for pancreatic Cancer treatment. Mol Cancer Ther. 2017;16(11):2399–409.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.